Search results
60 Results for 'Vaccines'
- Technologies (9)
- Collaborations (0)
- Team (0)
- News (41)
- Pages (0)
- Multimedia (10)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 9
-
DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy
Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
Cellular “Backpacks” to Fight Cancer, Autoimmune Disorders, and More
Macrophages are very malleable immune cells, but that also means that they can be influenced by cancerous tumors and inflammatory processes. Our cellular "backpacks" stick to macrophages and can deliver molecules that keep them in their desired state for cell therapy and more. -
eRNA: Enzymatic RNA synthesis for better drugs
EnPlusOne Biosciences is enabling RNA oligonucleotide manufacturing at scale, meeting the increasing demand for RNA drugs with an enzymatic process that is more efficient and creates a smaller environmental footprint. -
SPEAR: Ultrasensitive Protein Detection in Small Samples
Spear Bio uses a DNA nanotechnology-driven approach developed at the Wyss Institute that allows the sensitive detection of protein biomarkers in small samples using standard instruments to create new research and diagnostic assays. An ultra-sensitive assay detecting neutralizing antibodies against SARS-CoV-2 will be the first to be commercialized. -
DNA Nanotechnology Tools: From Design to Applications
A suite of diverse, multifunctional DNA nanotechnological tools with unique capabilities and potential for a broad range of clinical and biomedical research areas. Our DNA nanotechnology devices were engineered to overcome specific bottlenecks in the development of new therapies and diagnostics, and to help further our understanding of molecular structures. -
OMNIVAX: Broadly Deployable Infection Vaccine Platform
OMNIVAX is an immuno-material-based vaccine platform technology able to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial threats. Its modular approach enables the rapid creation of vaccines for pathogens using known and unknown antigens. Current approaches include vaccines against some viral diseases.
News 41
Multimedia 10
-
Video/AnimationDoriNano – Improved DNA Origami Nanodelivery to Fight Cancer and Other DiseasesWe’re developing DNA Origami nanodelivery, which is transforming nanoparticle industry. Developed at the Dana Farber Cancer Institute and the Wyss Institute at Harvard University, this innovative approach overcomes the challenges of other nanoparticles, offering stability, high drug loading capacity, nano-scale control of cargo spacing, and more – making it a highly customizable solution for delivering... -
Video/AnimationHow can we train the immune system to fight cancer?The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient’s own immune cells on-site to kill cancer cells. This revolutionary immuno-material technology was tested in a Phase I clinical trial with promising results and is currently licensed by Novartis as an immunotherapy to treat specific tumor types. Credit: Wyss Institute at Harvard... -
Video/AnimationDoriVac: Square Block DNA Origami VaccineThis animation explains how DoriVac leverages DNA origami nanotechnology and immune activators to stimulate stronger and long-lasting immune responses against cancer and potentially infectious diseases. Credit: Wyss Institute at Harvard University -
Video/AnimationThe Game-Changing Potential of mRNA VaccinesPromising mRNA vaccines years ago emerged from early-stage development, only to stall before proving themselves in clinical trials. Pushed by pandemic urgency across the notorious “Valley of Death,” this platform vastly exceeded expectations and is now poised to transform the vaccine R&D landscape. During the early months of the historic rollout of COVID-19 vaccines, Sabin’s... -
Video/AnimationOMNIVAX: Infection Vaccine PlatformThis video explains how OMNIVAX – an immuno-material-based vaccine technology can be used to rapidly create injectable vaccines against diverse viral and bacterial pathogens, and how the platform is used by the team to develop a vaccine against recurring urinary tract infections (UTIs) in their lead human application. Credit: Wyss Institute at Harvard University. -
Video/AnimationBeating Back the CoronavirusWhen the coronavirus pandemic forced Harvard University to ramp down almost all on-site operations, members of the Wyss Institute community refocused their teams, and formed new ones, in order to fight COVID-19 on its multiple fronts. These efforts include building new pieces of personal protective equipment that were delivered to frontline healthcare workers, developing new...